XML 88 R77.htm IDEA: XBRL DOCUMENT
v3.19.2

Segment Reporting - Sales of Company's Products (Details) - USD ($) $ in Millions | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2019 | Jun. 30, 2018 | Jun. 30, 2019 | Jun. 30, 2018
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 11,760 | $ 10,465 | $ 22,575 | $ 20,502
Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 11,632 | 10,428 | 22,359 | 20,496
Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 128 | 37 | 216 | 6
United States |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,144 | 4,262 | 9,659 | 8,395
United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,140 | 4,208 | 9,647 | 8,315
United States | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4 | 54 | 12 | 80
International |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,616 | 6,203 | 12,917 | 12,107
International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6,491 | 6,221 | 12,711 | 12,181
International | Other |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 125 | (18) | 206 | (74)
Total Pharmaceutical segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 10,460 | 9,282 | 20,123 | 18,201
Total Pharmaceutical segment sales | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 2,634 | 1,667 | 4,903 | 3,131
Total Pharmaceutical segment sales | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 121 | 148 | 237 | 273
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 111 | 44 | 190 | 76
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 97 | 35 | 171 | 35
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 886 | 608 | 1,724 | 1,269
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 675 | 426 | 1,171 | 818
Total Pharmaceutical segment sales | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 172 | 156 | 383 | 349
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 170 | 193 | 355 | 372
Total Pharmaceutical segment sales | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 58 | 65 | 105 | 101
Total Pharmaceutical segment sales | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 278 | 240 | 533 | 444
Total Pharmaceutical segment sales | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 193 | 188 | 383 | 363
Total Pharmaceutical segment sales | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 67 | 94 | 155 | 192
Total Pharmaceutical segment sales | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 78 | 149 | 150 | 300
Total Pharmaceutical segment sales | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 71 | 68 | 130 | 140
Total Pharmaceutical segment sales | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 67 | 87 | 129 | 178
Total Pharmaceutical segment sales | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 214 | 233 | 422 | 464
Total Pharmaceutical segment sales | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 157 | 221 | 324
Total Pharmaceutical segment sales | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 76 | 71 | 143 | 125
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 247 | 305 | 502 | 586
Total Pharmaceutical segment sales | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 108 | 113 | 221 | 243
Total Pharmaceutical segment sales | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 156 | 226 | 296 | 531
Total Pharmaceutical segment sales | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 76 | 155 | 174 | 322
Total Pharmaceutical segment sales | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 92 | 101 | 186 | 174
Total Pharmaceutical segment sales | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 104 | 75 | 194 | 143
Total Pharmaceutical segment sales | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 908 | 949 | 1,732 | 1,829
Total Pharmaceutical segment sales | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 533 | 585 | 1,063 | 1,129
Total Pharmaceutical segment sales | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 240 | 236 | 459 | 452
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 183 | 174 | 382 | 348
Total Pharmaceutical segment sales | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 160 | 185 | 352 | 360
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 109 | 125 | 213 | 245
Total Pharmaceutical segment sales | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 72 | 81 | 168 | 203
Total Pharmaceutical segment sales | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 75 | 84 | 149 | 166
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 63 | 70 | 121 | 138
Total Pharmaceutical segment sales | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,268 | 1,189 | 2,406 | 2,378
Total Pharmaceutical segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 4,758 | 3,841 | 8,933 | 7,557
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,498 | 959 | 2,782 | 1,797
Total Pharmaceutical segment sales | United States | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 67 | 89 | 130 | 168
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 66 | 31 | 116 | 55
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 19 | 104 | 19
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 456 | 302 | 818 | 682
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 500 | 356 | 843 | 668
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 104 | 99 | 258 | 250
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 123 | 122 | 248 | 234
Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 38 | 42 | 67 | 60
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 129 | 95 | 248 | 175
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 100 | 87 | 191 | 168
Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 22 | 48 | 64 | 95
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 18 | 87 | 31 | 177
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 1 | 5
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3 | 4 | 4 | 7
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 21 | 29 | 45 | 52
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 94 | 132 | 202 | 260
Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | (10) | 72 | (10)
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6 | 8 | 6 | 25
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 3 | 3 | 6 | 11
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 471 | 503 | 855 | 968
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 166 | 209 | 333 | 401
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 206 | 187 | 391 | 357
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 136 | 114 | 285 | 242
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 8 | 5 | 13 | 11
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 6 | 7 | 10 | 14
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | (1) | 0 | (2) | 2
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 0 | 0 | 0 | 0
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 24 | 27 | 53 | 56
Total Pharmaceutical segment sales | United States | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 401 | 287 | 759 | 608
Total Pharmaceutical segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 5,702 | 5,442 | 11,190 | 10,644
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,136 | 707 | 2,121 | 1,333
Total Pharmaceutical segment sales | International | Operating Segments | Emend |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 54 | 59 | 107 | 105
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 13 | 74 | 22
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 43 | 16 | 67 | 16
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 430 | 306 | 906 | 586
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 174 | 70 | 328 | 150
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 57 | 125 | 99
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23 |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 47 | 71 | 107 | 137
Total Pharmaceutical segment sales | International | Operating Segments | Vaqta |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 20 | 23 | 39 | 42
Total Pharmaceutical segment sales | International | Operating Segments | Bridion |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 149 | 145 | 285 | 269
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 93 | 100 | 192 | 195
Total Pharmaceutical segment sales | International | Operating Segments | Cubicin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 45 | 46 | 91 | 97
Total Pharmaceutical segment sales | International | Operating Segments | Invanz |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 60 | 63 | 118 | 123
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 70 | 68 | 129 | 135
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 64 | 83 | 125 | 171
Total Pharmaceutical segment sales | International | Operating Segments | Simponi |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 214 | 233 | 422 | 464
Total Pharmaceutical segment sales | International | Operating Segments | Remicade |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 98 | 157 | 221 | 324
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 55 | 42 | 98 | 73
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 153 | 174 | 300 | 326
Total Pharmaceutical segment sales | International | Operating Segments | Zepatier |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 68 | 123 | 149 | 253
Total Pharmaceutical segment sales | International | Operating Segments | Zetia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 150 | 218 | 290 | 505
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 73 | 152 | 167 | 311
Total Pharmaceutical segment sales | International | Operating Segments | Atozet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 92 | 101 | 186 | 174
Total Pharmaceutical segment sales | International | Operating Segments | Adempas |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 104 | 75 | 194 | 143
Total Pharmaceutical segment sales | International | Operating Segments | Januvia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 437 | 446 | 877 | 862
Total Pharmaceutical segment sales | International | Operating Segments | Janumet |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 366 | 377 | 730 | 729
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 34 | 49 | 68 | 95
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 60 | 98 | 106
Total Pharmaceutical segment sales | International | Operating Segments | Singulair |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 153 | 180 | 338 | 350
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 103 | 118 | 202 | 231
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 73 | 81 | 170 | 201
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 75 | 84 | 149 | 166
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 39 | 43 | 67 | 81
Total Pharmaceutical segment sales | International | Operating Segments | Other Pharmaceutical |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 869 | 902 | 1,650 | 1,770
Total Animal Health segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 1,124 | 1,090 | 2,149 | 2,155
Total Animal Health segment sales | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 671 | 633 | 1,282 | 1,286
Total Animal Health segment sales | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 453 | 457 | 867 | 869
Total Animal Health segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 335 | 311 | 628 | 618
Total Animal Health segment sales | United States | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 145 | 107 | 261 | 231
Total Animal Health segment sales | United States | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 190 | 204 | 367 | 387
Total Animal Health segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 789 | 779 | 1,521 | 1,537
Total Animal Health segment sales | International | Operating Segments | Livestock |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 526 | 526 | 1,021 | 1,055
Total Animal Health segment sales | International | Operating Segments | Companion Animals |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 263 | 253 | 500 | 482
Other segment sales | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 48 | 56 | 87 | 140
Other segment sales | United States | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | 47 | 56 | 86 | 140
Other segment sales | International | Operating Segments |  |  |  |
Segment Reporting Information [Line Items] |  |  |  |
Sales | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_EmendMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CubicinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_InvanzMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CancidasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZepatierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZetiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VytorinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AtozetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NuvaringMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ImplanonNexplanonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SingulairMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NasonexMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CozaarHyzaarMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ArcoxiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_FollistimAqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |